Article Information
History
- December 22, 2021.
Article Versions
- Version 1 (December 21, 2021 - 12:31).
- You are currently viewing Version 2 of this article (December 22, 2021 - 07:01).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Christian Holm Hansen, PhD*,1,
- Astrid Blicher Schelde, PhD*,1,
- Ida Rask Moustsen-Helm, PhD1,
- Hanne-Dorthe Emborg, PhD1,
- Tyra Grove Krause, PhD2,
- Kåre Mølbak2, DMSc,
- Palle Valentiner-Branth, PhD1,# and
- on behalf of the Infectious Disease Preparedness Group at Statens Serum Institut
- 1Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
- 2Epidemiological Infectious Diseases Preparedness Statens Serum Institut, Copenhagen, Denmark
- ↵#Correspondence:
Palle Valentiner-Branth, Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 2300 Copenhagen, Denmark, pvb{at}ssi.dk
↵* contributed equally
Posted December 22, 2021.
Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study
